Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality

被引:150
|
作者
Saha, Asim [1 ,2 ]
Aoyama, Kazutoshi [1 ,2 ]
Taylor, Patricia A. [1 ,2 ]
Koehn, Brent H. [1 ,2 ]
Veenstra, Rachelle G. [1 ,2 ]
Panoskaltsis-Mortari, Angela [1 ,2 ]
Munn, David H. [3 ]
Murphy, William J. [4 ]
Azuma, Miyuki [5 ]
Yagita, Hideo [6 ]
Fife, Brian T. [7 ,8 ]
Sayegh, Mohammed H. [9 ]
Najafian, Nader [9 ]
Socie, Gerard [10 ,11 ]
Ahmed, Rafi [12 ,13 ]
Freeman, Gordon J. [14 ]
Sharpe, Arlene H. [15 ,16 ]
Blazar, Bruce R. [1 ,2 ]
机构
[1] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Dept Pediat, Div Blood & Marrow Transplantat, Minneapolis, MN 55455 USA
[3] Med Coll Georgia, Dept Pediat, Sch Med, Augusta, GA 30912 USA
[4] Univ Calif Davis, Dept Dermatol, Davis, CA 95616 USA
[5] Tokyo Med & Dent Univ, Dept Mol Immunol, Tokyo, Japan
[6] Juntendo Univ, Sch Med, Dept Immunol, Tokyo 113, Japan
[7] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA
[8] Univ Minnesota, Ctr Immunol, Minneapolis, MN 55455 USA
[9] Brigham & Womens Hosp, Div Renal, Transplantat Res Ctr, Boston, MA 02115 USA
[10] Univ Paris 07, Hop St Louis, AP HP, Serv Hematol Greffe, Paris, France
[11] Unite Inst Natl Sante & Rech Med U940, Paris, France
[12] Emory Univ, Sch Med, Emory Vaccine Ctr, Atlanta, GA USA
[13] Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA
[14] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[15] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA USA
[16] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
基金
美国国家卫生研究院;
关键词
T-CELL-ACTIVATION; TNF-ALPHA; PD-1; TOLERANCE; RECEPTOR; PHOSPHORYLATION; LYMPHOCYTES; ENGAGEMENT; INHIBITOR; INTEGRINS;
D O I
10.1182/blood-2013-05-500801
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Programmed death 1 (PD-1) and its ligands, PD-L1 and PD-L2, play an important role in the maintenance of peripheral tolerance. We explored the role of PD-1 ligands in regulating graft-versus-host disease (GVHD). Both PD-L1 and PD-L2 expression were upregulated in the spleen, liver, colon, and ileum of GVHD mice. Whereas PD-L2 expression was limited to hematopoietic cells, hematopoietic and endothelial cells expressed PD-L1. PD-1/PD-L1, but not PD-1/PD-L2, blockade markedly accelerated GVHD-induced lethality. Chimera studies suggest that PD-L1 expression on host parenchymal cells is more critical than hematopoietic cells in regulating acute GVHD. Rapid mortality onset in PD-L1-deficient hosts was associated with increased gut T-cell homing and loss of intestinal epithelial integrity, along with increased donor T-cell proliferation, activation, Th1 cytokine production, and reduced apoptosis. Bioenergetics profile analysis of proliferating alloreactive donor T-cells demonstrated increased aerobic glycolysis and oxidative phosphorylation in PD-L1-deficient hosts. Donor T-cells exhibited a hyperpolarized mitochondrial membrane potential, increased superoxide production, and increased expression of a glucose transporter in PD-L1-deficient hosts. Taken together, these data provide new insight into the differential roles of host PD-L1 and PD-L2 and their associated cellular and metabolic mechanisms controlling acute GVHD.
引用
收藏
页码:3062 / 3073
页数:12
相关论文
共 50 条
  • [1] Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality
    Saha, Asim
    O'Connor, Roddy S.
    Thangavelu, Govindarajan
    Lovitch, Scott B.
    Dandamudi, Durga Bhavani
    Wilson, Caleph B.
    Vincent, Benjamin G.
    Tkachev, Victor
    Pawlicki, Jan M.
    Furlan, Scott N.
    Kean, Leslie S.
    Aoyama, Kazutoshi
    Taylor, Patricia A.
    Panoskaltsis-Mortari, Angela
    Foncea, Rocio
    Ranganathan, Parvathi
    Devine, Steven M.
    Burrill, Joel S.
    Guo, Lili
    Sacristan, Catarina
    Snyder, Nathaniel W.
    Blair, Ian A.
    Milone, Michael C.
    Dustin, Michael L.
    Riley, James L.
    Bernlohr, David A.
    Murphy, William J.
    Fife, Brian T.
    Munn, David H.
    Miller, Jeffrey S.
    Serody, Jonathan S.
    Freeman, Gordon J.
    Sharpe, Arlene H.
    Turka, Laurence A.
    Blazer, Bruce R.
    JOURNAL OF CLINICAL INVESTIGATION, 2016, 126 (07) : 2642 - 2660
  • [2] Contribution of Soluble Forms of Programmed Death 1 and Programmed Death Ligand 2 to Disease Severity and Progression in Systemic Sclerosis
    Fukasawa, Takemichi
    Yoshizaki, Ayumi
    Ebata, Satoshi
    Nakamura, Kouki
    Saigusa, Ryosuke
    Miura, Syunsuke
    Yamashita, Takashi
    Hirabayashi, Megumi
    Ichimura, Yohei
    Taniguchi, Takashi
    Asano, Yoshihide
    Shimizu, Hisashi
    Kazoe, Yutaka
    Mawatari, Kazuma
    Kitamori, Takehiko
    Sato, Shinichi
    ARTHRITIS & RHEUMATOLOGY, 2017, 69 (09) : 1879 - 1890
  • [3] Programmed Death-1 Pathway in Host Tissues Ameliorates Th17/Th1-Mediated Experimental Chronic Graft-versus-Host Disease
    Fujiwara, Hideaki
    Maeda, Yoshinobu
    Kobayashi, Koichiro
    Nishimori, Hisakazu
    Matsuoka, Ken-ichi
    Fujii, Nobuharu
    Kondo, Eisei
    Tanaka, Takehiro
    Chen, Lieping
    Azuma, Miyuki
    Yagita, Hideo
    Tanimoto, Mitsune
    JOURNAL OF IMMUNOLOGY, 2014, 193 (05) : 2565 - 2573
  • [4] Programmed death-ligand 1 expression in swine chronic infections and enhancement of interleukin-2 production via programmed death-1/programmed death-ligand 1 blockade
    Ganbaatar, Otgontuya
    Konnai, Satoru
    Okagawa, Tomohiro
    Nojima, Yutaro
    Maekawa, Naoya
    Ichikawa, Yoshiki
    Kobayashi, Atsushi
    Shibahara, Tomoyuki
    Yanagawa, Yojiro
    Higuchi, Hidetoshi
    Kato, Yukinari
    Suzuki, Yasuhiko
    Murata, Shiro
    Ohashi, Kazuhiko
    IMMUNITY INFLAMMATION AND DISEASE, 2021, 9 (04) : 1573 - 1583
  • [5] Association of disease activity with programmed cell death 1 and its ligand programmed cell death ligand 1 expressions in lupus patients
    Eissa, Eman
    Kandil, Rania
    El-Ghobashy, Nehal
    Abdelfattah, Walaa
    Hammouda, Zainab
    Gadelsayed, Sara Medhat
    Bayoumi, Faten
    INDIAN JOURNAL OF RHEUMATOLOGY, 2022, 17 (04) : 347 - 352
  • [6] Increased Programmed Death-1 Molecule Expression in Cytomegalovirus Disease and Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation
    Gallez-Hawkins, Ghislaine M.
    Thao, Lia
    Palmer, Joycelynne
    Dagis, Andrew
    Li, Xiuli
    Franck, Anne E.
    Tegtmeier, Bernard
    Lacey, Simon F.
    Diamond, Don J.
    Forman, Stephen J.
    Zaia, John A.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (07) : 872 - 880
  • [7] Programmed death 1 and programmed death ligand 1 expressions in patients with chronic hepatitis B
    Zhang, Wen-Jin
    Peng, Chuan-Hui
    Zheng, Shu-Sen
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2013, 12 (04) : 394 - 399
  • [8] Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma
    Cheah, Chan Yoon
    Fowler, Nathan H.
    Neelapu, Sattva S.
    CURRENT OPINION IN ONCOLOGY, 2015, 27 (05) : 384 - 391
  • [9] Assessment of programmed cell death 1 and its programmed cell death ligand 1 levels in vitiligo
    Nada, Hanan R.
    Mourad, Ahmed
    Rashed, Laila A.
    El-Hanafy, Ghada M.
    Abdallah, Nermeen M. A.
    Abdelhady, Mohamed M.
    JOURNAL OF EGYPTIAN WOMENS DERMATOLOGICAL SOCIETY, 2025, 22 (01): : 79 - 87
  • [10] Programmed death-ligand 1 expression in carcinoma of unknown primary
    Kim, Hye Min
    Koo, Ja Seung
    BMC CANCER, 2024, 24 (01)